Welcome to a fascinating excursion into the share price forecast for Mankind Pharma. In this post, we’ll look at the probable trajectory of the stock value of this pharmaceutical firm from 2023 to 2030. Share price objectives are rays of hope for investors looking for lucrative investments, and Mankind Pharma has attracted a lot of interest with its strong performance. Join us as we examine market trends, profit margins, and revenue growth to determine whether buying Mankind Pharma is a wise move. So buckle up and read on as we engrossingly investigate Mankind Pharma’s share price objective and reveal the crucial solution: Is it a decent company to buy?
Contents
Below are the trading platforms that you can use to purchase Mankind Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| May 2023 | ₹1,465.11 | ₹1,127.01 |
| June 2023 | ₹1,758.13 | ₹1,352.41 |
| July 2023 | ₹2,109.76 | ₹1,622.89 |
| August 2023 | ₹2,320.73 | ₹1,785.18 |
| September 2023 | ₹2,436.77 | ₹1,874.44 |
| October 2023 | ₹2,320.73 | ₹1,785.18 |
| November 2023 | ₹2,552.81 | ₹1,963.70 |
| December 2023 | ₹2,859.14 | ₹2,199.34 |
The table represents the predicted share prices for Mankind Pharma in 2023. The maximum price of the shares is projected to increase from ₹1,465.11 in May to ₹2,859.14 in December, indicating a significant growth percentage. Similarly, the minimum price is expected to rise from ₹1,127.01 to ₹2,199.34 during the same period. These numbers suggest a bullish trend for Mankind Pharma, with an overall uptrend in the share prices throughout the year. Investors can anticipate potential opportunities for growth and profitability based on this positive projection.
| When | Maximum Price | Minimum Price |
| January 2024 | ₹3,009.63 | ₹2,315.10 |
| February 2024 | ₹3,381.60 | ₹2,818.00 |
| March 2024 | ₹3,559.58 | ₹2,893.97 |
| April 2024 | ₹3,235.98 | ₹2,489.22 |
| May 2024 | ₹2,696.65 | ₹2,074.35 |
| June 2024 | ₹3,235.98 | ₹2,489.22 |
| July 2024 | ₹2,750.59 | ₹2,132.24 |
| August 2024 | ₹3,025.64 | ₹2,401.30 |
| September 2024 | ₹3,176.93 | ₹2,443.79 |
| October 2024 | ₹3,737.56 | ₹2,875.05 |
| November 2024 | ₹3,924.44 | ₹3,018.80 |
| December 2024 | ₹4,002.93 | ₹3,079.17 |
The projected share price targets for Mankind Pharma in 2024 indicate a mixed outlook. The maximum price is expected to reach ₹4,002.93 in December, while the minimum price target is estimated at ₹2,074.35 in May. This range suggests potential volatility in the share prices throughout the year. Investors should consider the potential return on investment with caution as the market may exhibit a bearish sentiment during certain periods. It is important to closely monitor market trends and company performance to make informed investment decisions. Overall, 2024 presents both opportunities and risks for investors interested in Mankind Pharma, and careful analysis and risk management are advised.
| When | Maximum Price | Minimum Price |
| January 2025 | ₹4,082.99 | ₹3,140.76 |
| February 2025 | ₹4,297.88 | ₹3,306.06 |
| March 2025 | ₹4,512.77 | ₹3,471.36 |
| April 2025 | ₹4,029.26 | ₹3,099.43 |
| May 2025 | ₹3,662.97 | ₹2,817.67 |
| June 2025 | ₹4,029.26 | ₹3,099.43 |
| July 2025 | ₹3,837.39 | ₹2,951.84 |
| August 2025 | ₹3,997.28 | ₹3,074.83 |
| September 2025 | ₹4,197.15 | ₹3,228.58 |
| October 2025 | ₹4,448.98 | ₹3,422.29 |
| November 2025 | ₹4,760.41 | ₹3,661.85 |
| December 2025 | ₹4,855.61 | ₹3,735.09 |
The share price targets for Mankind Pharma in 2025 present an optimistic outlook. The maximum price target is projected to reach ₹4,855.61 in December, while the minimum price target is estimated at ₹2,817.67 in May. This indicates a potential upside for investors, with the share prices expected to experience growth throughout the year. The average target price lies within the range of ₹4,029.26 to ₹3,099.43, suggesting a positive trajectory. Based on these projections, it may be recommended to consider Mankind Pharma as a potential investment option for 2025, taking into account the favorable price targets and the company’s performance in the pharmaceutical sector. However, it is crucial to conduct thorough research and seek professional advice before making any investment decisions.
| Year | Maximum Price | Minimum Price |
| 2023 | ₹2,859.14 | ₹1,127.01 |
| 2024 | ₹4,002.93 | ₹2,315.10 |
| 2025 | ₹4,855.61 | ₹3,099.43 |
| 2026 | ₹3,398.93 | ₹2,379.25 |
| 2027 | ₹2,889.09 | ₹2,022.36 |
| 2028 | ₹5,200.36 | ₹3,640.25 |
| 2029 | ₹10,682.35 | ₹7,477.64 |
| 2030 | ₹11,896.25 | ₹8,327.38 |
Mankind Pharma has shown consistent growth in its financial statements over the past five years. The company’s revenue has witnessed a steady increase from ₹3,829.06 crore in March 2019 to ₹8,127.15 crore in March 2023, indicating significant revenue growth. The net profit after tax (PAT) has also experienced consistent growth, reaching ₹1,248.26 crore in March 2023 from ₹514.04 crore in March 2019. This represents a substantial percentage growth in profit over the years. Additionally, the company has maintained a healthy operating profit margin (OPM) ranging from 18.41% to 25.95%, demonstrating its efficiency in managing expenses and generating profits. Mankind Pharma’s financial statements reflect a positive trend of increasing revenue and profit, showcasing its robust growth trajectory in the pharmaceutical industry.
Financial Condition of Mankind Pharma: Last 5 years
| Narration | Mar-19 | Mar-20 | Mar-21 | Mar-22 | Mar-23 |
| Sales | 3,829.06 | 4,794.41 | 5,523.18 | 7,257.04 | 8,127.15 |
| Expenses | 3,124.09 | 3,550.47 | 4,151.06 | 5,457.03 | 6,429.76 |
| Operating Profit | 704.97 | 1,243.94 | 1,372.12 | 1,800.01 | 1,697.39 |
| Other Income | 64.33 | 93.85 | 154.50 | 162.73 | 162.78 |
| Depreciation | 38.39 | 61.77 | 78.19 | 120.98 | 269.58 |
| Interest | 39.61 | 11.10 | 8.23 | 44.22 | 27.75 |
| Profit before tax | 691.30 | 1,264.92 | 1,440.20 | 1,797.54 | 1,562.84 |
| Tax | 177.26 | 306.70 | 355.83 | 462.41 | 314.58 |
| Net profit | 514.04 | 958.23 | 1,084.37 | 1,335.13 | 1,248.26 |
| EPS | 12.83 | 23.92 | 27.07 | 33.33 | 31.16 |
| Price to earning | |||||
| Price | – | – | – | – | – |
| RATIOS: | |||||
| Dividend Payout | 0.00% | 31.56% | 0.00% | 0.00% | 0.00% |
| OPM | 18.41% | 25.95% | 24.84% | 24.80% | 20.89% |
Mankind Pharma has shown consistent growth in its financial statements over the past five years. The company’s revenue has witnessed a steady increase from ₹3,829.06 crore in March 2019 to ₹8,127.15 crore in March 2023, indicating significant revenue growth. The net profit after tax (PAT) has also experienced consistent growth, reaching ₹1,248.26 crore in March 2023 from ₹514.04 crore in March 2019. This represents a substantial percentage growth in profit over the years. Additionally, the company has maintained a healthy operating profit margin (OPM) ranging from 18.41% to 25.95%, demonstrating its efficiency in managing expenses and generating profits. Mankind Pharma’s financial statements reflect a positive trend of increasing revenue and profit, showcasing its robust growth trajectory in the pharmaceutical industry.
Sharekhan on Mankind Pharma share price target
Sharekhan has given a buy call on Mankind Pharma. According to him, you can continue buying Mankind Pharma share with a target price of Rs1650.
Motilal Oswal on Mankind Pharma share price target
Motilal Oswal has given a buy call on Mankind Pharma. According to him, you can continue buying Mankind Pharma share with a target price of Rs1720.
FAQS
The share price target for Mankind Pharma in 2023-2030 is subject to market fluctuations and various factors. It is challenging to provide an exact target.
While it is uncertain whether Mankind Pharma’s share price will reach 5000 INR by 2025, the company has shown positive growth trends in recent years.
Factors such as revenue growth, profit growth, product pipeline, market conditions, and overall performance of the pharmaceutical industry influence Mankind Pharma’s share price growth.
How has Mankind Pharma’s financial performance been in the past?
Mankind Pharma has exhibited consistent revenue and profit growth over the past five years, which bodes well for potential share price growth.
Investing in any stock carries inherent risks. Factors like regulatory changes, competition, and unforeseen market conditions can impact Mankind Pharma’s share price.
Mankind Pharma’s EPS has shown growth over the years, indicating positive performance and potential for future share price appreciation.
Investors should conduct thorough research, analyze market trends, and consult with financial advisors to make informed decisions regarding investing in Mankind Pharma shares.
The historical data does not indicate dividend payouts by Mankind Pharma. However, dividend policies can change over time based on the company’s discretion.
What is the average annual growth rate of Mankind Pharma’s sales and profits?
The average annual growth rate of Mankind Pharma’s sales and profits can be calculated based on the historical financial data provided in their financial statements.
Share price targets are estimations and should not be the sole basis for investment decisions. It is essential to consider a comprehensive analysis of the company’s fundamentals, industry trends, and personal risk tolerance before making investment choices.
ALSO READ:
SHALIMAR PAINTS SHARE PRICE TARGET 2023-2030. CAN IT REACH 1000INR BY 2025?
TATA STEEL SHARE PRICE TARGET 2023-2030. CAN IT REACH 500INR BY 2025?
ULTRATECH CEMENT SHARE PRICE TARGET 2023-2030: CAN IT REACH 50000INR BY 2025?
Conclusion
In conclusion, Mankind Pharma’s shares seem to be a good investment option given on the company’s impressive income growth, PAT, sales growth, and profit growth during the last five years. Mankind Pharma has proven its potential to produce outstanding returns for shareholders with a significant increase in revenue from 3,829.06 crore in 2019 to 8,127.15 crore in 2023 and a commensurate development in net profit from 514.04 crore to 1,248.26 crore during the same period. The steady upward trend of these financial indicators points to a promising future for the company’s projected share price range of 2023 to 2030, making it an alluring investment opportunity.
